Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

78 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The RXR agonist bexarotene improves cholesterol homeostasis and inhibits atherosclerosis progression in a mouse model of mixed dyslipidemia.
Lalloyer F, Fiévet C, Lestavel S, Torpier G, van der Veen J, Touche V, Bultel S, Yous S, Kuipers F, Paumelle R, Fruchart JC, Staels B, Tailleux A. Lalloyer F, et al. Among authors: yous s. Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2731-7. doi: 10.1161/01.ATV.0000248101.93488.84. Epub 2006 Sep 28. Arterioscler Thromb Vasc Biol. 2006. PMID: 17008586
Rexinoid bexarotene modulates triglyceride but not cholesterol metabolism via gene-specific permissivity of the RXR/LXR heterodimer in the liver.
Lalloyer F, Pedersen TA, Gross B, Lestavel S, Yous S, Vallez E, Gustafsson JA, Mandrup S, Fiévet C, Staels B, Tailleux A. Lalloyer F, et al. Among authors: yous s. Arterioscler Thromb Vasc Biol. 2009 Oct;29(10):1488-95. doi: 10.1161/ATVBAHA.109.189506. Epub 2009 Jul 10. Arterioscler Thromb Vasc Biol. 2009. PMID: 19592467 Free PMC article.
Increased susceptibility of low-density lipoprotein to ex vivo oxidation in mice transgenic for human apolipoprotein B treated with 1 melatonin-related compound is not associated with atherosclerosis progression.
Tailleux A, Gozzo A, Torpier G, Martin-Nizard F, Bonnefont-Rousselot D, Lemdani M, Furman C, Foricher R, Chevé G, Yous S, Micard F, Bordet R, Gardes-Albert M, Lesieur D, Teissier E, Fruchart JC, Fiévet C, Duriez P. Tailleux A, et al. Among authors: yous s. J Cardiovasc Pharmacol. 2005 Sep;46(3):241-9. doi: 10.1097/01.fjc.0000175232.11079.7e. J Cardiovasc Pharmacol. 2005. PMID: 16116326
Novel 1,3-dicarbonyl compounds having 2(3H)-benzazolonic heterocycles as PPARgamma agonists.
Blanc-Delmas E, Lebegue N, Wallez V, Leclerc V, Yous S, Carato P, Farce A, Bennejean C, Renard P, Caignard DH, Audinot-Bouchez V, Chomarat P, Boutin J, Hennuyer N, Louche K, Carmona MC, Staels B, Pénicaud L, Casteilla L, Lonchampt M, Dacquet C, Chavatte P, Berthelot P, Lesieur D. Blanc-Delmas E, et al. Among authors: yous s. Bioorg Med Chem. 2006 Nov 15;14(22):7377-91. doi: 10.1016/j.bmc.2006.07.029. Epub 2006 Aug 2. Bioorg Med Chem. 2006. PMID: 16887353
Antioxydant activity of β-carboline derivatives in the LDL oxidation model.
Hadjaz F, Besret S, Martin-Nizard F, Yous S, Dilly S, Lebegue N, Chavatte P, Duriez P, Berthelot P, Carato P. Hadjaz F, et al. Among authors: yous s. Eur J Med Chem. 2011 Jun;46(6):2575-85. doi: 10.1016/j.ejmech.2011.03.048. Epub 2011 Mar 30. Eur J Med Chem. 2011. PMID: 21497423
78 results